Targeting Gut Microbiota for the Treatment of Primary Biliary Cholangitis:From Bench to Bedside  

作　　者：Li Zhang Ling Yang Huikuan Chu 

机构地区：[1]Division of Gastroenterology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,Hubei,China

出　　处：《Journal of Clinical and Translational Hepatology》2023年第4期958-966,共9页临床与转化肝病杂志（英文版）

基　　金：This study was supported by the National Natural Science Foundation of China(No.82000561 to HC,No.81974078,81570530,and 81370550 to LY);Natural Science Foundation of Hubei Province(No.2019ACA133 to LY);the Science Foundation of Union Hospital(No.2021xhyn005 to HC).

摘　　要：Primary biliary cholangitis(PBC)is a complex cholestatic liver disease with an unresolved etiology.The gut microbiota is composed of a dynamic community of bacteria,archaea,fungi,and viruses that have a key role in physiological processes related to nutrition,immunity,and host defense responses.A number of recent studies found that the composition of the gut microbiota of PBC patients was significantly altered,and reported that gut dysbiosis might arise during PBC development because of the close interactions of the liver and the gut.In light of the growing interest in this topic,the focus of this review is to characterize PBC gut microbiota alterations,the correlation between PBC pathology and the gut microbiota,and prospective therapies that target the altered gut microbiota,such as probiotics and fecal microbiota transplantation.

关 键 词：Primary biliary cholangitis Gut microbiota LIPOPOLYSACCHARIDES Bile acids PROBIOTICS Fecal microbiota transplantation 

分 类 号：R575[医药卫生—消化系统]